Combination of lovastatin and 2-deoxy-D-glucose increases the susceptibility of KRAS mutated human colorectal cancer cells to autophagy inhibition

RAS-driven colorectal cancer relies on glucose metabolism to support uncontrolled growth. However, monotherapy with glycolysis inhibitors like 2-deoxy-D-glucose exhibited limited effectiveness. Recent studies suggest that anti-tumor effects of glycolysis inhibition could be improved by combination treatment with inhibitors of oxidative phosphorylation. Our findings suggest that the combination of lovastatin and 2-deoxy-D-glucose may be a promising regimen concurrently targeting glycolysis, oxidative phosphorylation, and autophagy for the management of RAS-driven colorectal cancers. Supplementary S1 is "The effect of the combination of lovastatin and 2DG, and further inhibition of autophagy on cell proliferation in HCT-8 and CCD-841-CoN cell lines" and Supplementary S2-4 is the non-cropped images obtained from all three Western blotting experiments.